2003.-Certain angina and coronary artery disease forms do not respond to Ca 2ϩ channel blockers, and a role for vasoactive eicosanoids such as PGF2␣ in Ca 2ϩ antagonist-insensitive coronary vasospasm is suggested; however, the signaling mechanisms are unclear. We investigated whether PGF2␣-induced coronary smooth muscle contraction is Ca 2ϩ antagonist insensitive and involves activation of a PKC-dependent pathway. We measured contraction in single porcine coronary artery smooth muscle cells and intracellular free Ca 2ϩ concentration ([Ca 2ϩ ]i) in fura 2-loaded cells and examined cytosolic and particulate fractions for PKC activity and reactivity with isoform-specific PKC antibodies. In Hanks' solution (1 mM Ca 2ϩ ), PGF2␣ (10 Ϫ5 M) caused transient [Ca 2ϩ ]i increase followed by maintained [Ca 2ϩ ]i increase and 34% cell contraction. Ca 2ϩ channel blockers verapamil and diltiazem (10 Ϫ6 M) abolished maintained PGF2␣-induced [Ca 2ϩ ]i increase but only partially inhibited PGF2␣-induced cell contraction to 17%. Verapamil-insensitive PGF2␣ contraction was inhibited by PKC inhibitors GF-109203X, calphostin C, and ε-PKC V1-2. PGF2␣ caused Ca 2ϩ -dependent ␣-PKC and Ca 2ϩ -independent ε-PKC translocation from cytosolic to particulate fractions that was inhibited by calphostin C. Verapamil abolished PGF2␣-induced ␣-but not ε-PKC translocation. PMA (10 Ϫ6 M), a direct activator of PKC, caused 21% contraction with no significant [Ca 2ϩ ]i increase and ε-PKC translocation that were inhibited by calphostin C but not verapamil. Membrane depolarization by 51 mM KCl, which stimulates Ca 2ϩ influx, caused 36% cell contraction and [Ca 2ϩ ]i increase that were inhibited by verapamil but not GF-109203X or calphostin C and did not cause ␣-or ε-PKC translocation. Thus a significant component of PGF 2␣-induced contraction of coronary smooth muscle is Ca 2ϩ antagonist insensitive, involves Ca 2ϩ -independent ε-PKC activation and translocation, and may represent a signaling mechanism of Ca 2ϩ antagonist-resistant coronary vasospasm.
eicosanoids; calcium; vascular smooth muscle CORONARY VASOSPASM is often associated with ischemic heart disease leading to different forms of angina or myocardial infarction, and excessive coronary vasoconstriction in response to endogenous vasoconstrictors has been suggested as one potential cause (8, 18) .
Several potent endogenous vasoconstrictors have been described including certain vasoactive eicosanoids. Local release of endogenous vasoactive eicosanoids such as prostaglandin (PG)F 2␣ in response to cardiac tissue injury has been suggested to cause significant coronary vasoconstriction and to play a role in the setting of coronary vasospasm (3, 33, 37) . Clinical studies have shown accumulation of the isoprostane 8-epi-PGF 2␣ in patients with coronary artery disease (29) and increased production of 8-iso-PGF 2␣ in patients with acute myocardial infarction (24) . In addition, experimental studies in mice have shown that myocardial ischemia is associated with upregulation of cyclooxygenase (COX)-2 protein and activity and increased myocardial levels of COX-2 products such as PGE 2 , PGF 2␣ , and 6-keto-PGF 1␣ (42) . Among the methods of treatment of coronary artery disease, Ca 2ϩ channel blockers such as verapamil and diltiazem are often recommended to decrease coronary vasospasm and thereby reduce the incidence of angina and myocardial infarction (1, 2, 13, 35) . However, certain forms of angina and coronary artery disease do not respond adequately to treatment with Ca 2ϩ channel blockers (26, 38) . The causes of the Ca 2ϩ antagonistinsensitive forms of coronary vasospasm are not clearly understood, but they could be caused by decreased sensitivity of the coronary smooth muscle contraction induced by certain endogenous coronary vasoconstrictors to Ca 2ϩ channel blockers. For example, although PGF 2␣ is a potent coronary vasoconstrictor (3, 37) , the sensitivity of the PGF 2␣ -stimulated mechanisms of coronary smooth muscle contraction to Ca 2ϩ channel blockers is unclear.
Another potential cause of the Ca 2ϩ antagonist-insensitive forms of coronary vasospasm is possible activation of a Ca 2ϩ sensitization, or perhaps Ca 2ϩ -independent, mechanism(s) of smooth muscle contraction. It is widely accepted that vascular smooth muscle contraction is triggered by increases in intracellular free Ca 2ϩ concentration ([Ca 2ϩ ] i ) caused by Ca 2ϩ release from the intracellular stores and Ca 2ϩ entry from the extracellular space (12, 23, 36) . Also, the interaction of a vasoconstrictor agonist with its specific receptor is coupled to increased breakdown of plasma mem-brane phospholipids and increased production of diacylglycerol (DAG) (17, 34) . DAG binds to and activates protein kinase C (PKC). PKC is a family of Ca 2ϩ -dependent and Ca 2ϩ -independent isoforms that have different enzyme properties, substrates, and functions and exhibit different subcellular distributions in the same blood vessel type from different species and in different blood vessels from the same species (17, 20, 27, 34) . PKC is mainly cytosolic under resting conditions and undergoes translocation to the particulate fraction when it is activated by endogenous DAG or exogenous phorbol esters (17, 34) . In addition, direct activation of PKC by phorbol esters causes sustained contraction of vascular smooth muscle, suggesting a role for PKC in regulating smooth muscle contraction (14, 22) . However, the role of PKC as a potential signaling mechanism of the Ca 2ϩ antagonist-insensitive forms of coronary smooth muscle contraction has not been fully investigated.
The purpose of the present study was to test the hypothesis that a significant component of coronary smooth muscle contraction is Ca 2ϩ antagonist insensitive and involves activation of specific PKC isoforms. We used PGF 2␣ , a potent coronary vasoconstrictor, to induce coronary smooth muscle contraction. Because the PKC family includes both Ca 2ϩ -dependent and Ca 2ϩ -independent isoforms, any PGF 2␣ -induced changes in coronary smooth muscle [Ca 2ϩ ] i may determine which PKC isoform would be activated. Therefore, experiments were designed to investigate the effects of PGF 2␣ on coronary smooth muscle cell contraction, [Ca 2ϩ ] i , and PKC activity. The effects of PGF 2␣ were compared with those of phorbol 12-myristate 13-acetate (PMA), a direct activator of PKC, and with membrane depolarization by high-KCl solution, an activator of Ca 2ϩ entry from the extracellular space. The sensitivity of coronary smooth muscle cell contraction, [Ca 2ϩ ] i , and PKC activity to two Ca 2ϩ channel antagonists, namely verapamil and diltiazem, and mechanistically distinct PKC inhibitors, namely, GF-109203X, calphostin C, Gö-6976, and selective ε-PKC V1-2 inhibitory peptide (5-7, 25, 28, 39, 41) , was also investigated.
METHODS
Tissue preparation. Castrated male Yorkshire pigs (30 kg) from a local breeder were anesthetized by inhalation of isoflurane. The heart was rapidly excised and placed in Krebs solution. The left anterior descending coronary artery was dissected, cleaned of connective and adipose tissue, and opened by cutting along its longitudinal axis. The endothelium was removed by rubbing the vessel interior with wet filter paper. The tunica media was carefully dissected from the tunica adventitia under microscopic visualization with sharp-tipped forceps and then sectioned into 2 ϫ 2-mm strips. All procedures followed the guidelines of the Institutional Animal Care and Use Committee and the American Physiological Society.
Single-cell isolation. Coronary artery strips (50 mg) were placed in a tissue digestion mixture containing collagenase type II (236 U/mg protein; Worthington, Freehold, NJ), elastase grade II (3.25 U/mg protein; Boehringer Mannheim, Indianapolis, IN), and trypsin inhibitor type II (10,000 U/ml; Sigma, St. Louis, MO) in 7.5 ml of Ca 2ϩ -and Mg 2ϩ -free Hanks' solution supplemented with 30% bovine serum albumin (Sigma) as previously described (21, 30, 31) . The tissue was incubated three times in the tissue digestion mixture to yield three batches of cells. For batch 1, the tissue was incubated with 5 mg of collagenase, 4 mg of elastase, and 147 ml of trypsin inhibitor for 60 min. For batches 2 and 3, the tissue was incubated with 2.5 mg of collagenase, 4 mg of elastase, and 122 ml of trypsin inhibitor for additional 30 min. The tissue preparation was placed in a shaking water bath at 34°C in an atmosphere of 95% O 2-5% CO2. At the end of each incubation period, the preparation was rinsed with 12.5 ml of Hanks' solution with albumin. The first batch containing digested cells, damaged smooth muscle, and other unwanted material was discarded. Cells from both batches 2 and 3 were used and were poured over glass coverslips placed in wells and cooled to 2°C. The cells were allowed to settle by gravity and adhere to the glass coverslips. Ca 2ϩ was gradually added back to the preparation to avoid the "calcium paradox" (32) .
Contraction studies. Coverslips with the attached cells were placed on the stage of an inverted Nikon (Diaphot-300) microscope and viewed with a Nikon ϫ100 oil-immersion objective (total magnification ϫ1,000). The cells were bathed in 0.5 ml of Hanks' solution that remained stationary during the data recording. The cell isolation procedure yielded smooth muscle cells of variable lengths. Only viable, healthy, and spindle-shaped cells Ն60 m in length were selected. Viable, healthy cells adhered to the glass coverslips and appeared bright, with a halo along the periphery and without a visible nucleus when viewed with phase-contrast optics. The viability of the smooth muscle cells was confirmed by their exclusion of Trypan blue (0.2%; Sigma) and their consistent and significant contraction in response to PGF2␣ and high-KCl solution. The cells were further characterized and consistently showed significant immunofluorescence signal when fixed and labeled with anti-smooth muscle myosin antibody. Cell images were acquired with a PXL chargecoupled device camera and displayed on a PC with PMIS image analysis software (Photometrics, Tucson, AZ). The number of pixels corresponding to the cell length in the cell image was transformed into micrometers with a calibration bar. The steady-state changes in cell length were consistently measured after 10-min stimulation with PGF2␣ (10 Ϫ5 M) or KCl (51 mM) and after 30-min stimulation with the phorbol ester PMA (10 Ϫ6 M). The magnitude of cell contraction was expressed as the final cell length (L) as a fraction of the initial cell length (Li). All contraction measurements were made at 37°C.
Measurement of [Ca 2ϩ ]i. Single coronary smooth muscle cells were loaded with the Ca 2ϩ indicator fura 2 for 30 min at 34°C as previously described (19, 30, 31) . The fura 2 loading solution was made of normal Hanks' solution, the cell-permeant fura 2 acetoxymethyl ester (fura 2-AM, 10 Ϫ6 M; Molecular Probes, Eugene, OR), and 0.01% Pluronic F-127 (Sigma). The fura 2-loaded cells were washed twice and further incubated in Hanks' solution for at least 30 min to allow complete deesterification of the fura 2-AM. Precautionary measures were taken throughout the procedure to avoid extensive photobleaching of fura 2.
The fura 2-loaded cells were viewed through a Nikon Fluor ϫ100 oil-immersion objective (numerical aperture 1.3) on an inverted Nikon Diaphot-300 microscope. The Ca 2ϩ indicator was excited alternately at 340 and 380 nm with a filter wheel that alternated at a frequency of 0.5 Hz. The emitted light was collected at 510 nm into a R928 photomultiplier tube (Ludl Electronic Products, Hawthorne, NY) through a pin-hole aperture 1 m in diameter positioned 1 m from the plasma membrane and 1 m from the nucleus. The fluorescent signal was digitized with a module (Mac 2000; Ludl) and analyzed on a PC with data analysis software. The fluorescent signal was background subtracted. Spectral shifts that result from binding of Ca 2ϩ to fura 2 make it possible to use the ratio method, thus rendering the measurements of [Ca 2ϩ ]i less sensitive to changes in cell thickness or the extent of dye loading and photobleaching. The ratio between the fluorescence intensity at 340 and 380 nm (R) was transformed into the corresponding levels of [Ca 2ϩ ]i as described by Grynkiewicz and coworkers (10) .
where R min and Rmax represent the minimal and maximal fluorescence ratios and were measured by adding fura 2 pentapotassium salt (50 M) to Ca 2ϩ -free (10 mM EGTA) and Ca 2ϩ -replete (2 mM) solutions, respectively. Sf2/Sb2 is the ratio of the 380-nm signal in Ca 2ϩ -free and Ca 2ϩ -replete solutions, respectively. K d is the dissociation constant of fura 2 for Ca 2ϩ and was established at 224 nM under these experimental conditions (10) . All experiments were performed at 37°C.
Tissue fractions. Tissue strips (ϳ80 mg) under resting conditions or stimulated with PGF 2␣, PMA, or KCl for 30 min and in the absence or presence of the Ca 2ϩ channel blockers verapamil or diltiazem or the PKC inhibitors GF-109203X, calphostin C, Gö-6976, or ε-PKC V1-2 were used. The tissues were rapidly transferred to ice-cold equilibrating buffer A containing (in mM) 25 Tris ⅐ HCl (pH 7.5), 5 EGTA, 0.02 leupeptin, 0.2 phenylmethylsulfonyl fluoride, and 1 dithiothreitol. For measurement of PKC activity, the tissue was transferred to homogenization buffer B, which had the same composition as buffer A plus 250 mM sucrose. For Western blots, the tissue was transferred to a homogenization buffer containing 20 mM 3-(N-morpholino)propanesulfonic acid, 4% sodium dodecyl sulfate (SDS), 10% glycerol, 2.3 mg dithiothreitol, 1.2 mM EDTA, 0.02% bovine serum albumin, 5.5 M leupeptin, 5.5 M pepstatin, 2.15 M aprotinin and 20 M 4-(2-aminoethyl)-benzenesulfonyl fluoride. The tissue was homogenized with a 2-ml tight-fitting homogenizer (Kontes Glass) at 4°C and centrifuged at 100,000 rpm for 20 min at 4°C (Ultra-Centrifuge TL-100; Beckman), and the supernatant was used as the cytosolic fraction. The pellet was resuspended in homogenization buffer containing 1% Triton X-100 for 20 min, diluted with homogenization buffer to a final concentration of 0.2% Triton, and centrifuged at 100,000 rpm for 20 min at 4°C. The supernatant was used as the particulate fraction. Protein concentrations in tissue fractions were determined with a protein assay kit (Bio-Rad, Hercules, CA).
PKC activity. The cytosolic and particulate fractions were applied to diethylaminoethyl-cellulose columns (0.8 ϫ 4.0 cm; Bio-Rad). The columns were washed with buffer A, and the protein was eluted with 0.1 M NaCl. PKC activity in the aliquots was determined by measuring the incorporation of 32 P from [␥-
32 P]ATP (ICN) into histone III-S (15, 16). Because histone III-S may not be a good substrate for novel PKC isoforms such as ␦-and ε-PKC, experiments were also performed with myelin basic protein (MBP) as a substrate for PKC. The assay mixture contained 25 mM Tris ⅐ HCl (pH 7.5), 10 mM MgCl2, 200 g/ml histone III-S or MBP, 80 g/ml phosphatidylserine, 30 g/ml diolein, [␥-
32 P]ATP (1-3 ϫ 10 5 cpm/nmol), and 0.5-3 g of protein.
After 5-min incubation at 30°C, the reaction was stopped by spotting 25 l of the assay mixture onto phosphocellulose disks. The disks were washed 3 ϫ 5 min with 5% trichloroacetic acid and placed in 4 ml of Ecolite scintillation cocktail, and the radioactivity was measured in a liquid scintillation counter.
Immunoblotting. Protein-matched samples of the cytosolic and particulate fractions were subjected to electrophoresis on 8% SDS-polyacrylamide gels and then transferred electrophoretically to nitrocellulose membranes. The membranes were incubated in 5% dried nonfat milk in phosphate-buffered saline (PBS)-Tween at 22°C for 1 h, washed with PBSTween 3 ϫ 5 min, and then incubated in the primary anti-PKC antibody solution at 4°C overnight. Polyclonal antibodies to ␣-, ␤-, ␥-, ␦-, ε-, and -PKC (GIBCO, Grand Island, NY) were used. These antibodies have been shown to react with the specific PKC isoforms in porcine aortic endothelial cells and airway and coronary smooth muscle (11, 15, 16, 40) . The specificity of each antibody was routinely verified by demonstrating that it was blocked by the synthetic peptide to which the antibody was raised and not by other sequences of the PKC molecule, a more stringent control than simple elimination of the primary antibody. To keep the labeling conditions constant, we used the same anti-PKC antibody titer (1:500) and protein concentration (10 g) in all tissue samples. These antibody titer and protein concentrations gave optimal immunoreactive signals while remaining on the linear portion of the titration curve. To confirm the results with the GIBCO polyclonal antibodies, we also used polyclonal anti-PKC antibodies from Sigma (1:500), polyclonal anti-PKC antibodies from Chemicon International (Temecula, CA; 1:100), and monoclonal anti-PKC antibodies from Seikagaku America (Ijamsville, MD; 1:100) and obtained similar results. The nitrocellulose membranes were washed 5 ϫ 15 min in PBS-Tween and then incubated in horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgG for 1.5 h. The blots were washed with PBS-Tween 5 ϫ 15 min and visualized with enhanced chemiluminescence detection system (Amersham, Arlington Heights, IL). PBS-Tween contained (in mM) 80 Na 2HPO4, 20 NaH2PO4, 100 NaCl, and 0.05% Tween. The reactive bands corresponding to PKC isoforms were analyzed quantitatively by optical densitometry with a GS-700 imaging densitometer (Bio-Rad).
Solutions. Krebs solution contained (in mM) 120 NaCl, 5.9 KCl, 2. Drugs and chemicals. PGF 2␣ (Sigma), verapamil, and diltiazem (Calbiochem, La Jolla, CA) were dissolved in distilled water. Neomycin sulfate and 1-[6-([17␤-3-methoxyestra-1,3,5(10)trien-17-yl]amino)hexyl]-1H-pyrrole-2,5-dione (U-73122) were purchased from Biomol (Plymouth Meeting, PA). PMA (Alexis, San Diego, CA), GF-109203X (Biomol), Gö-6976 (Biomol), calphostin C (Kamiya, Tukwila, WA), and myristoyl-tagged membrane-permeant ε-PKC V1-2 inhibitory peptide (Biomol) were dissolved in dimethyl sulfoxide (DMSO). The final concentration of DMSO in solution was Յ0.1%. All other chemicals were of reagent grade or better.
Statistical analysis. The data were analyzed and presented as means Ϯ SE and compared by Student's t-test for unpaired data, with P Ͻ 0.05 considered significant.
RESULTS
The cell isolation procedure produced relatively long coronary smooth muscle cells (Fig. 1) (Fig. 1B) (Fig. 1D) . A small, transient PGF 2␣ -induced increase in [Ca 2ϩ ] i to 121 Ϯ 13 nM could still be observed in cells pretreated with verapamil plus GF-109203X (Fig. 1D) (Figs. 2C and 3) . Pretreat- ] i , the verapamil-insensitive PGF 2␣ contraction, or PMA contraction (Fig. 3) . On the other hand, the membrane-permeant selective ε-PKC V1-2 inhibitory peptide (10 Ϫ4 M) (5, 6, 9) abolished the verapamil-insensitive component of PGF 2␣ contraction and the PMA contraction, with no change in [Ca 2ϩ ] i (Fig. 3) . Neither Gö-6976 nor ε-PKC V1-2 caused any significant inhibition of KCl-induced contraction or [Ca 2ϩ ] i . In resting tissues PKC activity was greater in the cytosolic than the particulate fraction, and the particulate-to-cytosolic ratio was 0.5 Ϯ 0.1. PGF 2␣ (10 Ϫ5 M) caused an increase in PKC activity in the particulate fraction and a decrease in the cytosolic fraction (Fig.  4A ) and a significant increase in the particulate-tocytosolic ratio to a maximum of 2.1 Ϯ 0.2 (Fig. 4B) . In tissues pretreated with verapamil (10 Ϫ6 M) the PGF 2␣ -induced PKC activity was partially, but significantly, reduced (Fig. 4, B and C) . Partial, but significant, reduction of the PGF 2␣ -induced particulate-to-cytosolic PKC ratio to 1.2 Ϯ 0.1 was also observed in tissues pretreated with diltiazem (10 Ϫ6 M). On the other hand, pretreating the tissues with the PKC inhibitor GF-109203X (10 Ϫ6 M) abolished the PGF 2␣ -induced increases in PKC activity (Fig. 4, B and C) . Complete inhibition of PGF 2␣ -induced PKC activity was also observed in tissues pretreated with the PKC inhibitor calphostin C (10 Ϫ6 M). Treatment of the tissues for 30 min with Gö-6976 (10 Ϫ6 M), a relatively specific inhibitor of Ca 2ϩ -dependent PKC isoforms (28), did not significantly affect the verapamil-insensitive component of the PGF 2␣ -induced PKC activity ratio (1.3 Ϯ 0.2). On the other hand, the ε-PKC V1-2 inhibitory peptide (10 Ϫ4 M) decreased the verapamil-insensitive PGF 2␣ -induced PKC activity ratio to 0.6 Ϯ 0.1, which was not significantly different from the basal PKC activity ratio.
In comparison with PGF 2␣ , the phorbol ester PMA (10 Ϫ6 M) caused significant increases in PKC activity that were inhibited by GF-109203X or calphostin C but not by verapamil (Fig. 4C) . In tissues stimulated with KCl depolarizing solution (51 mM) no significant increases in PKC activity could be observed, and pretreating the tissues with verapamil, diltiazem, GF-109203X, or calphostin C did not cause any significant change in PKC activity (Fig. 4C) .
Western blot analysis revealed significant amounts of ␣-, ␦-, ε-, and -PKC. In resting unstimulated tissues, ␣-and ε-PKC appeared to be mainly cytosolic (Fig. 5) , ␦-PKC was slightly more in the particulate fraction, and -PKC was equally distributed in the cytosolic and particulate fractions as previously described (15, 16) . PGF 2␣ caused significant translocation of the Ca 2ϩ -dependent ␣-PKC (Fig. 5A ) and the Ca 2ϩ -independent ε-PKC (Fig. 5B ) from the cytosolic to the particulate fraction. Pretreating the tissues with the Ca 2ϩ channel blocker verapamil inhibited the PGF 2␣ -induced translocation of ␣-PKC (Fig. 5A) but not ε-PKC (Fig. 5B) . On the other hand, the PKC inhibitor calphostin C, but not GF-109203X, inhibited the PGF 2␣ -induced transloca- tion of both ␣-PKC (Fig. 5A) and ε-PKC (Fig. 5B) . The phorbol ester PMA did not cause translocation of ␣-PKC but induced translocation of ε-PKC that was inhibited in tissues pretreated with calphostin C but not GF-109203X.
Experiments in Ca 2ϩ -free (2 mM EGTA) solution indicated that significant PGF 2␣ -induced cell contraction, PKC activity, and ε-PKC translocation could still be observed in the absence of extracellular Ca 2ϩ entry (Fig. 6) . The PGF 2␣ -induced cell contraction, PKC activity, and ε-PKC translocation in Ca 2ϩ -free solution were inhibited in tissues pretreated with the selective ε-PKC V1-2 inhibitory peptide (Fig. 6) .
DISCUSSION
The main findings of the present study are as follows. 3) The PKC inhibitors GF-109203X, calphostin C, and ε-PKC V1-2, but not Gö-6976, inhibit the verapamil-insensitive component of the PGF 2␣ -induced contraction and PKC activity. 4) Calphostin C and ε-PKC V1-2, but not GF-109203X, inhibit the PGF 2␣ -induced translocation of ε-PKC. 5) The PGF 2␣ -induced contraction, PKC activity, and ε-PKC translocation in the absence of Ca 2ϩ entry in Ca 2ϩ -free solution were inhibited by the selective ε-PKC V1-2 peptide.
The interaction of an agonist with its receptor is known to activate the enzyme phospholipase C and to increase the hydrolysis of phosphatidylinositol 4,5-bisphosphate into inositol 1,4,5-trisphosphate and DAG (16, 17, 34) . Inositol 1,4,5-trisphosphate stimulates Ca 2ϩ release from the intracellular stores, and DAG stimulates PKC (17, 34) . The inhibition of PGF 2␣ -induced cell contraction by the phospholipase C inhibitors neomycin and U-73122 provides evidence that the PGF 2␣ responses involve activation of phospholipase C and the hydrolysis of plasma membrane phospholipids.
The (23, 36) , other contraction pathways have been suggested, including activation of PKC (12, 17) . Several studies have shown that direct activation of PKC by phorbol esters causes significant and sustained contraction of smooth muscle with no significant change in [Ca 2ϩ ] i (14, 22) , suggesting a role for PKC in regulating smooth muscle contraction, at least in part, by increasing the myofilament force sensitivity to [Ca 2ϩ ] i . To investigate the role of PKC in the Ca 2ϩ antagonist-insensitive component of PGF 2␣ contraction, we compared the PGF 2␣ response with that of a direct PKC activator such as the phorbol ester PMA. PMA caused significant cell contraction that is most likely due to activation of PKC because 1) PMA caused contraction in the absence of detectable changes in [Ca 2ϩ ] i ; 2) PMA caused significant increases in PKC activity; and 3) the PMA-induced contraction and PKC activity were inhibited by the PKC inhibitors GF-109203X and calphostin C but not by verapamil. The observation that GF-109203X or calphostin C, at a concentration that completely inhibits PMA-induced contraction and PKC activity, caused significant inhibition of PGF 2␣ contraction suggests that a significant component of PGF 2␣ contraction involves activation of PKC. Also, the combined pretreatment of the cells with GF-109203X or calphostin C and the Ca 2ϩ antagonist verapamil, which are partial inhibitors of PGF 2␣ contraction, completely inhibited the PGF 2␣ contraction. These data suggest that GF-109203X or calphostin C inhibits the Ca 2ϩ antagonist-insensitive component of PGF 2␣ and provide evidence that the Ca 2ϩ antagonistinsensitive component of PGF 2␣ involves activation of PKC. This is supported by the present observation that PGF 2␣ causes significant increase in PKC activity that is inhibited by the PKC inhibitors GF-109203X and calphostin C.
PKC is a family of Ca 2ϩ -dependent and Ca 2ϩ -independent isoforms (17, 34) . The present immunoblotting data suggest that in Ca 2ϩ -containing solution PGF 2␣ causes activation and translocation of both the Ca 2ϩ -dependent ␣-PKC and the Ca 2ϩ -independent ε-PKC. The PGF 2␣ -induced translocation of ␣-and ε-PKC is inhibited by the PKC inhibitor calphostin C, confirming the specificity of the PKC translocation assay. On the other hand, verapamil inhibited the PGF 2␣ -induced translocation of ␣-PKC but not that of ε-PKC. The inhibition of ␣-PKC translocation by the Ca 2ϩ antagonist verapamil is consistent with reports that ␣-PKC is a Ca 2ϩ -dependent isoform (17, 34) . On the other hand, the lack of inhibition of ε-PKC by verapamil is in accordance with the reports that ε-PKC is a Ca 2ϩ -independent isoform (17, 34) -independent PKC isoforms.
2) The Ca 2ϩ antagonist-insensitive PGF 2␣ contraction and PKC activity were inhibited by the specific ε-PKC V1-2 inhibitory peptide. 3) Under conditions in which Ca 2ϩ entry was minimized in Ca 2ϩ -free (2 mM EGTA) solution, significant PGF 2␣ contraction, PKC activity, and ε-PKC translocation could still be observed. 4) The PGF 2␣ -induced contraction, PKC activity, and ε-PKC translocation in Ca 2ϩ -free solution were inhibited in tissues pretreated with the selective ε-PKC V1-2 inhibitory peptide and thus further support the contention that a portion of PGF 2␣ contraction is Ca 2ϩ insensitive and involves activation of the Ca 2ϩ -independent ε-PKC.
In the present study, the phorbol ester PMA, a PKC activator, caused contraction with no significant increase in [Ca 2ϩ ] i and induced significant activation and translocation of ε-PKC, consistent with a possible role for ε-PKC in Ca 2ϩ -insensitive smooth muscle contraction. The question arises as to why PMA did not activate ␣-PKC at basal levels of [Ca 2ϩ ] i whereas PGF 2␣ caused significant activation of ␣-PKC when [Ca 2ϩ ] i was increased above basal levels. This could be related, at least in part, to the level of [Ca 2ϩ ] i required for activation of Ca 2ϩ -dependent PKC isoforms. This is consistent with previous reports that a threshold increase in [Ca 2ϩ ] i is required for activation of ␣-PKC in vascular smooth muscle cells of the ferret and the pig (16, 19) . We should also note that the PKC inhibitor calphostin C inhibited both the PGF 2␣ -and PMA-induced translocation of ␣-or ε-PKC as well as PKC activity. However, GF-109203X did not inhibit PGF 2␣ -or PMA-induced translocation of ␣-or ε-PKC despite its complete inhibition of PKC activity. This could be explained by the difference in the site of action of calphostin C and GF-109203X on the PKC molecule. GF-109203X and calphostin C are two mechanistically distinct PKC inhibitors. GF-109203X inhibits the PKC enzyme by interfering with ATP binding to the catalytic domain and therefore would inhibit the PKC phosphotransferase activity without inhibiting its translo-cation (41) . On the other hand, calphostin C competes with PMA or DAG for binding to the regulatory domain and therefore inhibits both PKC translocation and phosphotransferase activity (7, 25, 39) . This may also explain the observation that ε-PKC V1-2, a 14-to 21-peptide sequence derived from the first variable region V1 of the regulatory domain of ε-PKC (5, 6), prevented ε-PKC translocation and significantly inhibited Ca 2ϩ -insensitive PKC activity. The cellular mechanisms of PGF 2␣ contraction in the absence of significant increases in [Ca 2ϩ ] i are not entirely clear but may involve G protein-induced activation of phospholipases (4) . The observed inhibition of PGF 2␣ -induced cell contraction by the phospholipase C inhibitors neomycin and U-73122 provides evidence that the PGF 2␣ responses involve activation of phospholipase C and the hydrolysis of plasma membrane phospholipids. The increased phospholipid turnover leads to increased DAG production and activation of ε-PKC. ε-PKC could then cause phosphorylation, either directly or indirectly, of actin-binding proteins such as calponin or caldesmon and thereby lead to increased force sensitivity of the contractile proteins even to basal levels of [Ca 2ϩ ] i (12 -independent ε-PKC, and may represent a possible signaling mechanism of the Ca 2ϩ antagonist-resistant forms of coronary vasospasm.
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